Investigator Site Audit Performance - Applied Clinical Trials

ADVERTISEMENT

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
See our 2009 Buyers Guide Digital Edition.
Find Pharma Search Engine
Investigator Site Audit Performance
CQA benchmark survey finds companies use a similar method to conduct and report audits.


Applied Clinical Trials


Categorization of findings


Main Categories Used for Audit Findings
All participating companies, with the exception of one, assign audit findings to process related categories, such as "informed consent," "study protocol compliance," or "safety reporting." Most companies use similar categories for the critical processes that are subject to an audit (see Figure 2). All companies utilizing such categorizations use the categories "safety reporting" and "informed consent." Approximately 90% use the categories "IRB/IEC," "source documents," "drug supply handling," and "protocol compliance," and approximately 80% use the categories "essential documents," "study personnel and agreements," "monitoring," and "data accuracy/SDV." Each of the 14 categories provided in the survey is used by at least 66% of the companies. Additional categories not specifically listed in the questionnaire—such as "trial management," "training," and "computer validation"—are also used by some companies.

Classification of findings

Almost 80% of the companies evaluate the significance of each single audit finding and state this in the audit report. The most frequent classifications used are "critical," "major," and "minor."

In addition, one fourth of the companies have a system or rule to evaluate the significance of each category, stating the overall evaluation of all findings related to each one (e.g., informed consent).

About 50% of the companies classify the overall outcome of site audits. Half of them use predefined classifications, while the other half provide narratives. If predefined classifications are used, they are similar to those used for single audit findings.

Reporting of findings

About 70% of the companies have a multistep reporting process implemented (e.g., draft/final reports); the other companies have a single-step reporting process in place.

For approximately 85% of the companies, the audit report contains an executive summary, which is normally distributed as part of the full audit report.

All companies, with the exception of one, apply QC measures to the audit report generation process—most after peer reviews, conducted by either an auditor colleague or line manager within QA.

Draft and final report

Around 90% of the companies make the draft and/or the final audit report available to the auditees. Two companies neither provide the draft nor the final report to the auditees. About 30% of the companies do not provide management with the draft report, but 97% do provide them with the final report. Only one company doesn't make the draft or the final audit report available to management.

Approximately 50% of the companies send the audit report to other affected functions (e.g., regulatory affairs, regional organization members, training, purchasing, etc.), but from the available information, no pattern could be identified.

Time frame for reporting


Length of Time to Report Audits
The defined time frame between the conduct of the audit and the release of the report varies between 5 and 40 working days (median of 15 working days, mean of 16.6 working days). Thirty-four percent need to issue the report within two weeks, 59% within three weeks, and 76% within four weeks. Ten percent of the companies need to issue the audit report after more than five weeks. Two companies have no defined timeline for the availability of the audit report (see Figure 3).

Critical audit findings

Expedited Reporting. Two-thirds of the companies report critical findings in an expedited manner. Some companies stated that critical findings have to be reported to QA senior management and/or appropriate clinical management either immediately (i.e., during the audit conduct) or within up to 5 working days by phone, email, or meeting.

Clinical study reports. About 60% of the companies report critical audit findings and/or corresponding corrective actions in their final clinical study report.

IRBs/IECs and agencies. Only 17% of the companies report critical audit findings and/or corresponding corrective actions directly to IRBs/IECs and agencies.

Recommendations/requests for corrective actions. Two-thirds of the audit reports contain recommendations or requests for corrective actions for either critical findings or major findings. About half of the audit reports contain recommendations or requests for corrective actions for minor findings. Fourteen percent of the companies do not give recommendations or requests of this kind at all in their audit reports.

Responding to reports/findings

All companies, except one, request responses to each of their audit reports. This company, though, expects responses in the case of critical or major findings as well. In terms of addressing individual findings, all companies expect critical and major findings to be individually addressed. Still, 83% of the companies expect a response to minor findings.

Responsibility for replying. In about 60% of the companies the study manager and the monitor are both responsible for replying to audit findings; in six of the companies, this responsibility lies with either one. Thus, in 80% of the companies at least one of these two individuals is responsible for replying.

In half of the companies, line management is involved in providing responses: For eight companies, in addition to the monitor or the study manager, line management is responsible for replying. In six companies, only line management is responsible for addressing audit findings.


ADVERTISEMENT

ADVERTISEMENT

Enrollment Planning for Critical Path Studies
Successful Outsourcing: Tracking Global CRO Usage
Solutions to the Discovered Challenges of Informed Consent
Training Investigators and IRB in Asia
An EMR Update
FindPharma
Survey
Would you ever consider working as a freelance clinical research professional?
Yes, I'd love to
Yes, but would never do it
No, but may have to
Absolutely not, no stability
Yes, I'd love to
75%
Yes, but would never do it
8%
No, but may have to
17%
Absolutely not, no stability
0%
View Results
Source: Applied Clinical Trials,
Click here